Bluebird Bio Sells Priority Review Voucher For $102M, Strengthening Its Financial Position

Bluebird Bio Inc has agreed to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $102 million.
Bluebird was granted two PRVs upon the FDA approvals of Zynteglo (betibeglogene autotemcel) for beta-thalassemia in adult and pediatric patients requiring regular red blood cell transfusions and Skysona (elivaldogene autotemcel) for early, active cerebral adrenoleukodystrophy.